Back to Insights

What does COMPASS Pathways’ recent data on psilocybin mean for psychedelic therapies?

Posted by Blue Matter on November 30th, 2021.

In early November of 2021, COMPASS Pathways released phase IIb data on its psilocybin-based therapy for treatment-resistant depression. Varun Renjen, M.D., leader of our CNS team, talks about this data and its implications for COMPASS (and for psychedelics in CNS therapy overall).